Colistin. Renaissance of an old antibiotic?;Colistin Ein altes Antibiotikum in neuem Glanz?

Internist

Volumn 54, Issue 8, 2013, Pages 936-944

  Stocker, H ^a   Kern, W V ^b  

^a Vivantes Auguste Viktoria Klinikum   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Colistimethate sodium; Gram negative bacteria; Multidrug resistance; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CARBAPENEM DERIVATIVE; COLISTIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; RECOMMENDED DRUG DOSE;

ANTI-BACTERIAL AGENTS; COLISTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EVIDENCE-BASED MEDICINE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84888005941     PISSN: 00209554     EISSN: 14321289     Source Type: Journal    
DOI: 10.1007/s00108-012-3141-3     Document Type: Article

References (36)

1. Bergen PJ, Bulitta JB, Forrest A et al (2010) Pharmacokinetic/ pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 54:3783-3789
2. Bergen PJ, Li J, Rayner CR et al (2006) Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:1953-1958
3. Betrosian AP, Frantzeskaki F, Xanthaki A et al (2008) Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. J Infect 56:432-436
4. Brink AJ, Coetzee J, Corcoran C et al (2013) Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract. J Clin Microbiol 51:369-372
5. Chen G, Thamlikitkul V, Jacob J et al (2011) Plasma protein binding of colistin in critically-ill patients receiving intravenous colistin methanesulfonate. 51st ICAAC. Chicago, USA
6. Corvec S, Furustrand Tafin U, Betrisey B et al (2013) Activities of fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum- beta-lactamase-producing Escherichia coli in a foreign-body infection model. Antimicrob Agents Chemother 57:1421-1427
7. Couet W, Gregoire N, Gobin P et al (2011) Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89:875-879
8. Dalfino L, Puntillo F, Mosca A et al (2012) High dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54:1720-1726
9. Dudhani RV, Turnidge JD, Nation RL et al (2010) fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother 65:1984-1990
10. Durakovic N, Radojcic V, Boban A et al (2011) Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med 50:1009-1013
11. Everson NA, Davis SL, Bloome M et al (2011) Are optimized doses of colistimethate associated with more nephrotoxicity? 51st ICAAC. Chicaco, USA
12. Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ et al (2003) Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 36:1111-1118
13. Garonzik SM, Li J, Thamlikitkul V et al (2011) Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically-ill patients from a multi-center study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:3284-3294
14. Gounden R, Bamford C, Van Zyl-Smit R et al (2009) Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 9:26
15. Hornsey M, Wareham DW (2011) In vivo efficacy of glycopeptide/colistin combination therapies in a Galleria mellonella model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 55:3534-3537
16. Kallel H, Hergafi L, Bahloul M et al (2007) Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 33:1162-1167
17. Li J, Nation RL (2006) Comment on: pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 58:222-223
18. Li J, Nation RL, Milne RW et al (2005) Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 25:11-25
19. Li J, Nation RL, Owen RJ et al (2007) Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 45:594-598
20. Li J, Turnidge J, Milne R et al (2001) In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 45:781-785
21. Moffatt JH, Harper M, Harrison P et al (2010) Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54:4971-4977
22. Mojoli F, Iotti GA, Imberti R et al (2013) The importance of protecting the mechanical ventilator during colistin methanesulfonate nebulization. Intensive Care Med 39:535-536
23. Montero A, Ariza J, Corbella X et al (2004) Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54:1085-1091
24. Nanjo Y, Ishii Y, Kimura S et al (2011) Effects of colistin slow-releasing microspheres on endotoxin-induced sepsis. 51st ICAAC. Chicago, USA
25. Orwa J, Van Gerven A, Roets E et al (2000) Development and validation of a liquid chromatography method for analysis of colistin sulphate. Chromatographia 51:433-436
26. Paul M, Bishara J, Levcovich A et al (2010) Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother 65:1019-1027
27. Plachouras D, Karvanen M, Friberg LE et al (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53:3430-3436
28. Qureshi ZA, Paterson DL, Potoski BA et al (2012) Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56:2108-2113
29. Ratjen F, Rietschel E, Kasel D et al (2006) Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 57:306-311
30. Rattanaumpawan P, Lorsutthitham J, Ungprasert P et al (2010) Randomized controlled trial of nebulized colistimethate sodium as adjunctive therapy of ventilator-associated pneumonia caused by Gram-negative bacteria. J Antimicrob Chemother 65:2645-2649
31. Rios FG, Luna CM, Maskin B et al (2007) Ventilator-associated pneumonia due to colistin susceptible-only microorganisms. Eur Respir J 30:307-313
32. Sbrana F, Malacarne P, Viaggi B et al (2013) Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 56:697-700
33. Shields RK, Clancy CJ, Gillis LM et al (2012) Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One 7:e52349
34. Vaara M (1991) The outer membrane permeability-increasing action of linear analogues of polymyxin B nonapeptide. Drugs Exp Clin Res 17:437-443
35. Velkov T, Thompson PE, Nation RL et al (2010) Structure-activity relationships of polymyxin antibiotics. J Med Chem 53:1898-1916
36. Yousef JM, Chen G, Hill PA et al (2012) Ascorbic acid protects against the nephrotoxicity and apoptosis caused by colistin and affects its pharmacokinetics. J Antimicrob Chemother 67:452-459